EGIDO, Jesús et al. The pleiotropic effects of paricalcitol: beyond bone-mineral metabolism. []. , 36, 1, pp.10-18. ISSN 1989-2284.  https://dx.doi.org/10.1016/j.nefro.2015.11.003.

Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.

: Vitamin D; Secondary hyperparathyroidism; Parathyroid hormone; Vascular calcification; Atherosclerosis; Proteinuria; Dialysis; Transplant.

        · |     · |     · ( pdf )